Skip to Content

Jennifer Wang

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

As an active member of SWOG (Southwest Oncology Group) I am able to contribute to a cooperative group that designs and conducts multidisciplinary clinical trials that exist to improve the practice of detection, prevention and treatment of cancer. In particular, I’m currently involved in a phase III randomized clinical trial study involving androgen deprivation therapy and orteronel to see how well it works compared to androgen deprivation therapy and bicalutamide in treating patients with newly diagnosed prostate cancer that has spread to other places in the body. Androgen deprivation therapy suppresses or blocks the production or action of male hormones. Androgens can cause the growth of prostate cancer cells. Drugs, such as orteronel and bicalutamide, may lessen the amount of androgens made by the body. This trial will assist us in gaining more knowledge to whether or not giving androgen deprivation therapy with orteronel or bicalutamide is more effective in treating prostate cancer. With my continued support in these studies, I am able to become more involved in the process of integrating main campus department trials into the regional care centers.

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler St.
Houston, Texas, TX 77030
Room Number: CPB7.3462
Phone: 713-792-2830
Fax: 713-745-1625
MD Anderson Cancer Center Regional Care Sugar Land
1327 Lake Pointe Parkway
Suite 200
Sugar Land, TX 77478
Phone: 281-566-1900
Fax: 281-566-1901

Education & Training

Degree-Granting Education

2007 Baylor College of Medicine, Houston, TX, TX, MD, Medicine
2003 Duke University, Durham, NC, BS, Cum Laude, Anthropology and Anatomy

Postgraduate Training

7/2010-6/2013 Clinical Fellowship, Hematology/Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
6/2007-7/2010 Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX

Board Certifications

11/2013 American Board of Hematology
11/2013 American Board of Medical Oncology
8/2010 American Board of Internal Medicine


Administrative Appointments/Responsibilities

Departmental Regional Care Center Liaison, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2013-present

Professional Memberships

American Society of Clinical Oncology
Member, 2010-present
MD Anderson Cancer Center GU Medical Oncology Departmental Regional Care Center, Houston, TX
Liaison, 2015-present
SWOG (Southwest Oncology Group), Portland, OR
Member, Principal Investigator, 5/2015-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Wang J, Pettaway CA, Pagliaro LC. Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes. Urology 85(5):1104-10, 5/2015. e-Pub 3/2015. PMID: 25819619.
2. Wang J, Wei C, Noor R, Burke A, McIntyre S, Bedikian AY. Surveillance for brain metastases in patients receiving systemic therapy for advanced melanoma. Melanoma Res 24(1):54-60, 10/2013. PMID: 24121189.
3. Graham BH, Li Z, Alesii EP, Versteken P, Lee C, Wang J, Craigen WJ. Neurologic dysfunction and male infertility in Drosophila porin mutants: a new model for mitochondrial dysfunction and disease. J Biol Chem 285(15):11143-53, 4/9/2010. e-Pub 1/28/2010. PMCID: PMC2856991.
4. Fisher D, Jeffreys A, Bosworth H, Wang J, Lipscomb J, Provenzale D. Quality of life in patients with Barrett's esophagus undergoing surveillance. Am J Gastroenterol 97(9):2193-200, 9/2002. PMID: 12358232.


1. Wang J, Rodriguez J, Pao P, Pettaway CA, Pagliaro LC. Programmed death ligand-1 (PD-L1) expression in penile squamous cell carcinoma. 2015 Genitourinary Cancers Symposium (#393), 2/2015.
2. Wang J, Tu SM, Pagliaro LC, Weiss M, Haidenberg J, Tseng J, Wade JL, Belt RJ, Cannon MW, Fisch M. A prospective randomized phase III trial comparing consolidation therapy with or without strontium-89 following induction chemotherapy in androgen-independent prostate cancer. J Clin Oncol 32(suppl 4) (#90), 2014.
3. Wang J, Patel S, Huw WJ, Kim K, Papadopoulos N, Hwu P, Radvanyi L, Mahoney S, Debutt T, Basset R, Bedikian A. Development of brain metastases in patients with metastatic melanoma treated with ipilimumab plus temozolomide. J Clin Oncol (#e19014), 2012.
4. Mougalian S, Wang J, Zarzour MA, Quinn D, Rieber A. Feasibility and savings of a suspicion of cancer clinic at a large county hospital. ASCO Quality Care Symposium (#104), 2012.
5. Wang J, Pettaway CA, Pagliaro LC. Salvage treatment for metastatic penile cancer after the first line chemotherapy with paclitaxel, ifosfamide, and cisplatin: Analysis of response and survival outcomes. GU ASCO Symposium proceedings (#340), 2012.
6. Wang J. Mesenteric fibromatosis as a unusual cause of abdominal pain. J Gen Intern Medicine (#(S1): S331), 4/2009.
7. Paul Gettys Corn, Wang J. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). 2015 ASCO Annual Meeting (#5010). Submitted.
8. Brian Francis Chapin, Wang J. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metasttatic prostate cancer. 2015 ASCO Annual Meeting (#TPS5075). Submitted.

Book Chapters

1. Wang J, Pagliaro L. Chemotherapy in the Combined Modality Treatment of Penile Carcinoma. In: Neoadjuvant Chemotherapy. Ed(s) O. Bathe. Neoadjuvant Chemotherapy: Croatia, 2012.

Last updated: 11/10/2015